img

Global Oncology Immunotherapy Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Oncology Immunotherapy Market Insights, Forecast to 2034

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body's own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
Market Analysis and InsightsGlobal Oncology Immunotherapy Market
Global Oncology Immunotherapy market is expected to reach to US$ 2365 million in 2024, with a positive growth of %, compared with US$ 2251 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Oncology Immunotherapy industry is evaluated to reach US$ 3807.5 million in 2029. The CAGR will be 8.3% during 2024 to 2029.
The Oncology Immunotherapy market has expanded as a groundbreaking approach to treating cancer by harnessing the body's immune system to target and fight cancer cells. This innovative therapy includes immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, among others. By enhancing the immune response against tumors, immunotherapy offers potentially durable and targeted treatments, often with fewer side effects compared to traditional approaches. The market's growth is driven by promising clinical outcomes and a growing understanding of immune-tumor interactions. As researchers continue to explore and refine immunotherapeutic strategies, the Oncology Immunotherapy market remains at the forefront of oncology, revolutionizing cancer treatment paradigms and offering new hope to patients.
Report Covers
This report presents an overview of global Oncology Immunotherapy market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Oncology Immunotherapy market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Bristol-Myers Squibb
Merck & Co
Roche AG
AstraZeneca
Sanofi S.A.
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc.
Merck KGaA
Segment by Type
Immune Checkpoint Inhibitors
Cytokine-Based Immunotherapy
Cancer Vaccines
CAR-T Cell Therapy
Other

Segment by Application


Hospitals
Drugstores
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Oncology Immunotherapy introduction, etc. Oncology Immunotherapy Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Oncology Immunotherapy
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Oncology Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Market by Application
1.3.1 Global Oncology Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Oncology Immunotherapy Market Perspective (2018-2029)
2.2 Global Oncology Immunotherapy Growth Trends by Region
2.2.1 Oncology Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Oncology Immunotherapy Historic Market Size by Region (2018-2024)
2.2.3 Oncology Immunotherapy Forecasted Market Size by Region (2024-2029)
2.3 Oncology Immunotherapy Market Dynamics
2.3.1 Oncology Immunotherapy Industry Trends
2.3.2 Oncology Immunotherapy Market Drivers
2.3.3 Oncology Immunotherapy Market Challenges
2.3.4 Oncology Immunotherapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Oncology Immunotherapy by Players
3.1.1 Global Oncology Immunotherapy Revenue by Players (2018-2024)
3.1.2 Global Oncology Immunotherapy Revenue Market Share by Players (2018-2024)
3.2 Global Oncology Immunotherapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Oncology Immunotherapy, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Oncology Immunotherapy Market Concentration Ratio
3.4.1 Global Oncology Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Oncology Immunotherapy Revenue in 2022
3.5 Global Key Players of Oncology Immunotherapy Head office and Area Served
3.6 Global Key Players of Oncology Immunotherapy, Product and Application
3.7 Global Key Players of Oncology Immunotherapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Oncology Immunotherapy Breakdown Data by Type
4.1 Global Oncology Immunotherapy Historic Market Size by Type (2018-2024)
4.2 Global Oncology Immunotherapy Forecasted Market Size by Type (2024-2029)
5 Oncology Immunotherapy Breakdown Data by Application
5.1 Global Oncology Immunotherapy Historic Market Size by Application (2018-2024)
5.2 Global Oncology Immunotherapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Oncology Immunotherapy Market Size (2018-2029)
6.2 North America Oncology Immunotherapy Market Size by Type
6.2.1 North America Oncology Immunotherapy Market Size by Type (2018-2024)
6.2.2 North America Oncology Immunotherapy Market Size by Type (2024-2029)
6.2.3 North America Oncology Immunotherapy Market Share by Type (2018-2029)
6.3 North America Oncology Immunotherapy Market Size by Application
6.3.1 North America Oncology Immunotherapy Market Size by Application (2018-2024)
6.3.2 North America Oncology Immunotherapy Market Size by Application (2024-2029)
6.3.3 North America Oncology Immunotherapy Market Share by Application (2018-2029)
6.4 North America Oncology Immunotherapy Market Size by Country
6.4.1 North America Oncology Immunotherapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Oncology Immunotherapy Market Size by Country (2018-2024)
6.4.3 North America Oncology Immunotherapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Oncology Immunotherapy Market Size (2018-2029)
7.2 Europe Oncology Immunotherapy Market Size by Type
7.2.1 Europe Oncology Immunotherapy Market Size by Type (2018-2024)
7.2.2 Europe Oncology Immunotherapy Market Size by Type (2024-2029)
7.2.3 Europe Oncology Immunotherapy Market Share by Type (2018-2029)
7.3 Europe Oncology Immunotherapy Market Size by Application
7.3.1 Europe Oncology Immunotherapy Market Size by Application (2018-2024)
7.3.2 Europe Oncology Immunotherapy Market Size by Application (2024-2029)
7.3.3 Europe Oncology Immunotherapy Market Share by Application (2018-2029)
7.4 Europe Oncology Immunotherapy Market Size by Country
7.4.1 Europe Oncology Immunotherapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Oncology Immunotherapy Market Size by Country (2018-2024)
7.4.3 Europe Oncology Immunotherapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Oncology Immunotherapy Market Size (2018-2029)
8.2 China Oncology Immunotherapy Market Size by Type
8.2.1 China Oncology Immunotherapy Market Size by Type (2018-2024)
8.2.2 China Oncology Immunotherapy Market Size by Type (2024-2029)
8.2.3 China Oncology Immunotherapy Market Share by Type (2018-2029)
8.3 China Oncology Immunotherapy Market Size by Application
8.3.1 China Oncology Immunotherapy Market Size by Application (2018-2024)
8.3.2 China Oncology Immunotherapy Market Size by Application (2024-2029)
8.3.3 China Oncology Immunotherapy Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Oncology Immunotherapy Market Size (2018-2029)
9.2 Asia Oncology Immunotherapy Market Size by Type
9.2.1 Asia Oncology Immunotherapy Market Size by Type (2018-2024)
9.2.2 Asia Oncology Immunotherapy Market Size by Type (2024-2029)
9.2.3 Asia Oncology Immunotherapy Market Share by Type (2018-2029)
9.3 Asia Oncology Immunotherapy Market Size by Application
9.3.1 Asia Oncology Immunotherapy Market Size by Application (2018-2024)
9.3.2 Asia Oncology Immunotherapy Market Size by Application (2024-2029)
9.3.3 Asia Oncology Immunotherapy Market Share by Application (2018-2029)
9.4 Asia Oncology Immunotherapy Market Size by Region
9.4.1 Asia Oncology Immunotherapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Oncology Immunotherapy Market Size by Region (2018-2024)
9.4.3 Asia Oncology Immunotherapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Oncology Immunotherapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Oncology Immunotherapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Oncology Immunotherapy Introduction
11.1.4 Bristol-Myers Squibb Revenue in Oncology Immunotherapy Business (2018-2024)
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Company Details
11.2.2 Merck & Co Business Overview
11.2.3 Merck & Co Oncology Immunotherapy Introduction
11.2.4 Merck & Co Revenue in Oncology Immunotherapy Business (2018-2024)
11.2.5 Merck & Co Recent Developments
11.3 Roche AG
11.3.1 Roche AG Company Details
11.3.2 Roche AG Business Overview
11.3.3 Roche AG Oncology Immunotherapy Introduction
11.3.4 Roche AG Revenue in Oncology Immunotherapy Business (2018-2024)
11.3.5 Roche AG Recent Developments
11.4 AstraZeneca
11.4.1 AstraZeneca Company Details
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Oncology Immunotherapy Introduction
11.4.4 AstraZeneca Revenue in Oncology Immunotherapy Business (2018-2024)
11.4.5 AstraZeneca Recent Developments
11.5 Sanofi S.A.
11.5.1 Sanofi S.A. Company Details
11.5.2 Sanofi S.A. Business Overview
11.5.3 Sanofi S.A. Oncology Immunotherapy Introduction
11.5.4 Sanofi S.A. Revenue in Oncology Immunotherapy Business (2018-2024)
11.5.5 Sanofi S.A. Recent Developments
11.6 Dendreon Pharmaceuticals
11.6.1 Dendreon Pharmaceuticals Company Details
11.6.2 Dendreon Pharmaceuticals Business Overview
11.6.3 Dendreon Pharmaceuticals Oncology Immunotherapy Introduction
11.6.4 Dendreon Pharmaceuticals Revenue in Oncology Immunotherapy Business (2018-2024)
11.6.5 Dendreon Pharmaceuticals Recent Developments
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Oncology Immunotherapy Introduction
11.7.4 Novartis Revenue in Oncology Immunotherapy Business (2018-2024)
11.7.5 Novartis Recent Developments
11.8 Gilead Sciences Inc.
11.8.1 Gilead Sciences Inc. Company Details
11.8.2 Gilead Sciences Inc. Business Overview
11.8.3 Gilead Sciences Inc. Oncology Immunotherapy Introduction
11.8.4 Gilead Sciences Inc. Revenue in Oncology Immunotherapy Business (2018-2024)
11.8.5 Gilead Sciences Inc. Recent Developments
11.9 Merck KGaA
11.9.1 Merck KGaA Company Details
11.9.2 Merck KGaA Business Overview
11.9.3 Merck KGaA Oncology Immunotherapy Introduction
11.9.4 Merck KGaA Revenue in Oncology Immunotherapy Business (2018-2024)
11.9.5 Merck KGaA Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Oncology Immunotherapy Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Immune Checkpoint Inhibitors
Table 3. Key Players of Cytokine-Based Immunotherapy
Table 4. Key Players of Cancer Vaccines
Table 5. Key Players of CAR-T Cell Therapy
Table 6. Key Players of Other
Table 7. Global Oncology Immunotherapy Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Oncology Immunotherapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Oncology Immunotherapy Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Oncology Immunotherapy Market Share by Region (2018-2024)
Table 11. Global Oncology Immunotherapy Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Oncology Immunotherapy Market Share by Region (2024-2029)
Table 13. Oncology Immunotherapy Market Trends
Table 14. Oncology Immunotherapy Market Drivers
Table 15. Oncology Immunotherapy Market Challenges
Table 16. Oncology Immunotherapy Market Restraints
Table 17. Global Oncology Immunotherapy Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Oncology Immunotherapy Revenue Share by Players (2018-2024)
Table 19. Global Top Oncology Immunotherapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immunotherapy as of 2022)
Table 20. Global Oncology Immunotherapy Industry Ranking 2021 VS 2022 VS 2024
Table 21. Global 5 Largest Players Market Share by Oncology Immunotherapy Revenue (CR5 and HHI) & (2018-2024)
Table 22. Global Key Players of Oncology Immunotherapy, Headquarters and Area Served
Table 23. Global Key Players of Oncology Immunotherapy, Product and Application
Table 24. Global Key Players of Oncology Immunotherapy, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Oncology Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Oncology Immunotherapy Revenue Market Share by Type (2018-2024)
Table 28. Global Oncology Immunotherapy Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Oncology Immunotherapy Revenue Market Share by Type (2024-2029)
Table 30. Global Oncology Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Oncology Immunotherapy Revenue Share by Application (2018-2024)
Table 32. Global Oncology Immunotherapy Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Oncology Immunotherapy Revenue Share by Application (2024-2029)
Table 34. North America Oncology Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 35. North America Oncology Immunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Oncology Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 37. North America Oncology Immunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Oncology Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Oncology Immunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 40. North America Oncology Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Oncology Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 42. Europe Oncology Immunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Oncology Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 44. Europe Oncology Immunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Oncology Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Oncology Immunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 47. Europe Oncology Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Oncology Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 49. China Oncology Immunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Oncology Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 51. China Oncology Immunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Oncology Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 53. Asia Oncology Immunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Oncology Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 55. Asia Oncology Immunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Oncology Immunotherapy Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Oncology Immunotherapy Market Size by Region (2018-2024) & (US$ Million)
Table 58. Asia Oncology Immunotherapy Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Type (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Application (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Oncology Immunotherapy Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Country (2018-2024) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size by Country (2024-2029) & (US$ Million)
Table 66. Bristol-Myers Squibb Company Details
Table 67. Bristol-Myers Squibb Business Overview
Table 68. Bristol-Myers Squibb Oncology Immunotherapy Product
Table 69. Bristol-Myers Squibb Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 70. Bristol-Myers Squibb Recent Developments
Table 71. Merck & Co Company Details
Table 72. Merck & Co Business Overview
Table 73. Merck & Co Oncology Immunotherapy Product
Table 74. Merck & Co Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 75. Merck & Co Recent Developments
Table 76. Roche AG Company Details
Table 77. Roche AG Business Overview
Table 78. Roche AG Oncology Immunotherapy Product
Table 79. Roche AG Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 80. Roche AG Recent Developments
Table 81. AstraZeneca Company Details
Table 82. AstraZeneca Business Overview
Table 83. AstraZeneca Oncology Immunotherapy Product
Table 84. AstraZeneca Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 85. AstraZeneca Recent Developments
Table 86. Sanofi S.A. Company Details
Table 87. Sanofi S.A. Business Overview
Table 88. Sanofi S.A. Oncology Immunotherapy Product
Table 89. Sanofi S.A. Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 90. Sanofi S.A. Recent Developments
Table 91. Dendreon Pharmaceuticals Company Details
Table 92. Dendreon Pharmaceuticals Business Overview
Table 93. Dendreon Pharmaceuticals Oncology Immunotherapy Product
Table 94. Dendreon Pharmaceuticals Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 95. Dendreon Pharmaceuticals Recent Developments
Table 96. Novartis Company Details
Table 97. Novartis Business Overview
Table 98. Novartis Oncology Immunotherapy Product
Table 99. Novartis Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 100. Novartis Recent Developments
Table 101. Gilead Sciences Inc. Company Details
Table 102. Gilead Sciences Inc. Business Overview
Table 103. Gilead Sciences Inc. Oncology Immunotherapy Product
Table 104. Gilead Sciences Inc. Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 105. Gilead Sciences Inc. Recent Developments
Table 106. Merck KGaA Company Details
Table 107. Merck KGaA Business Overview
Table 108. Merck KGaA Oncology Immunotherapy Product
Table 109. Merck KGaA Revenue in Oncology Immunotherapy Business (2018-2024) & (US$ Million)
Table 110. Merck KGaA Recent Developments
Table 111. Research Programs/Design for This Report
Table 112. Key Data Information from Secondary Sources
Table 113. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Oncology Immunotherapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Oncology Immunotherapy Market Share by Type: 2022 VS 2029
Figure 3. Immune Checkpoint Inhibitors Features
Figure 4. Cytokine-Based Immunotherapy Features
Figure 5. Cancer Vaccines Features
Figure 6. CAR-T Cell Therapy Features
Figure 7. Other Features
Figure 8. Global Oncology Immunotherapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Oncology Immunotherapy Market Share by Application: 2022 VS 2029
Figure 10. Hospitals Case Studies
Figure 11. Drugstores Case Studies
Figure 12. Others Case Studies
Figure 13. Oncology Immunotherapy Report Years Considered
Figure 14. Global Oncology Immunotherapy Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Oncology Immunotherapy Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Oncology Immunotherapy Market Share by Region: 2022 VS 2029
Figure 17. Global Oncology Immunotherapy Market Share by Players in 2022
Figure 18. Global Top Oncology Immunotherapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immunotherapy as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Oncology Immunotherapy Revenue in 2022
Figure 20. North America Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Oncology Immunotherapy Market Share by Type (2018-2029)
Figure 22. North America Oncology Immunotherapy Market Share by Application (2018-2029)
Figure 23. North America Oncology Immunotherapy Market Share by Country (2018-2029)
Figure 24. United States Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Oncology Immunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Oncology Immunotherapy Market Share by Type (2018-2029)
Figure 28. Europe Oncology Immunotherapy Market Share by Application (2018-2029)
Figure 29. Europe Oncology Immunotherapy Market Share by Country (2018-2029)
Figure 30. Germany Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Oncology Immunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Oncology Immunotherapy Market Share by Type (2018-2029)
Figure 38. China Oncology Immunotherapy Market Share by Application (2018-2029)
Figure 39. Asia Oncology Immunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Oncology Immunotherapy Market Share by Type (2018-2029)
Figure 41. Asia Oncology Immunotherapy Market Share by Application (2018-2029)
Figure 42. Asia Oncology Immunotherapy Market Share by Region (2018-2029)
Figure 43. Japan Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Oncology Immunotherapy Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Oncology Immunotherapy Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Oncology Immunotherapy Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Oncology Immunotherapy Market Share by Country (2018-2029)
Figure 53. Brazil Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Oncology Immunotherapy Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Bristol-Myers Squibb Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 60. Merck & Co Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 61. Roche AG Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 62. AstraZeneca Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 63. Sanofi S.A. Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 64. Dendreon Pharmaceuticals Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 65. Novartis Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 66. Gilead Sciences Inc. Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 67. Merck KGaA Revenue Growth Rate in Oncology Immunotherapy Business (2018-2024)
Figure 68. Bottom-up and Top-down Approaches for This Report
Figure 69. Data Triangulation
Figure 70. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries